8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Learn More →

Join Veristat and over 1000 big pharma, biotech, payers, and patient advocate groups at the World Orphan Drug Congress 2017.
Topics will include the following:
Veristat is passionate about helping clients accelerate their rare disease therapies for unmet medical needs through the clinical development process. With over 350 million rare disease sufferers worldwide today, the urgency for more treatments is paramount. Veristat is proud to have worked on over 235 rare disease treatments so far!
Nearly a third of our clinical trial work is for rare and ultra rare diseases! Learn more about our rare disease experience.
To meet up with Veristat at this event or to connect with us at anytime, fill out the form on the right side of this page. If you are attending the World Orphan Drug Congress 2017, you can request to connect with Eric Monroe or Kate Bentley through the conference partnering system.
We look forward to connecting with you soon!
8 min read
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...
8 min read
Aug 14, 2026 Veristat Blog
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...